Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 12/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021757 | 1.00 | PPARD (0.48) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL3021922 | 0.88 | PPARD (0.49) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL3021925 | 0.88 | PPARD (0.49) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL3025213 | 0.86 | PPARD (0.51) | PPARDPPARAPPARGSMN1; SMN2 | |
| SCHEMBL3025219 | 0.86 | PPARD (0.51) | PPARDPPARAPPARGSMN1; SMN2 | |
| SCHEMBL3026854 | 0.84 | PPARD (0.69) | PPARDPPARA | |
| SCHEMBL3026852 | 0.84 | PPARD (0.69) | PPARDPPARA | |
| SCHEMBL1244089 | 0.84 | PPARD (0.50) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL3030246 | 0.82 | PPARA (0.45) | PPARDPPARAPPARGSMN1; SMN2 | |
| SCHEMBL3030250 | 0.82 | PPARA (0.45) | PPARDPPARAPPARGSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.